Staff Introduction

Full-time Lecturer Kazuma Yagi

Research Areas
Infectious diseases, Infection control, Mycobacterial infections, Respiratory medicine, Microbiome in the Field of Infectious Diseases
Kazuma Yagi

Career

March 2008
M.D. Keio University School of Medicine, Tokyo
April 2008
Residency Program, Shizuoka Red Cross Hospital, Shizuoka
April 2010
Senior Residency Program, Department of Medicine, Keio University Hospital
April 2011
Senior Residency Program, Department of General Internal Medicine, Saiseikai Yokohamashi Tobu Hospital
April 2012
Clinical Fellow, Division of Pulmonary Medicine, Department of Medicine, Keio University Hospital
April 2016
Medical Doctor Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center
July 2019
Medical Doctor Department of Pulmonary Medicine, Keiyu Hospital
October 2020
Research Fellow/ Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
October 2023
Medical Doctor Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital
April 2025
Current Position

Qualifications

  • Specialist in Internal Medicine, The Japanese Society of Internal Medicine

    Specialist in Infectious Diseases, The Japanese Association for Infectious Diseases

    Respiratory Specialist, The Japanese Respiratory Society

    Tuberculosis and Mycobacterial Disease Specialist, The Japanese Society for Tuberculosis

    ICD (Infectious Disease Control), endorsed by the Japanese Association for Infectious Diseases

    Certified Bronchoscopist, Japanese Association for Chest Surgery

Degree

  • Doctor of Medicine (M.D., Ph.D.)

Current Research Focus and Aspirations

Our bodies host diverse microorganisms, including gut bacteria (the microbiome), which play vital roles in maintaining health. We aim to elucidate how these microbes influence resistance to infectious diseases and affect disease progression. Specifically, we seek to uncover the relationship between these microorganisms and chronic respiratory infections affecting the lungs, such as non-tuberculous mycobacterial lung disease. Our goal is to identify new biomarkers that could aid in the prevention and treatment of these diseases.